Ardelyx Inc - Understand $ardx stock

$ARDX Market Cap: $1.389 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$210.0M

TTM

Gross Margin

85.8%

TTM

Net Earnings

-$65.15M

TTM

Current Assets

$263.0M

Q2 2024

Current Liabilities

$62.44M

Q2 2024

Current Ratio

421.26%

Q2 2024

Total Assets

$343.5M

Q2 2024

Total Liabilities

$196.5M

Q2 2024

Book Value

$147.0M

Q2 2024

Cash

$41.89M

Q2 2024

P/E

-21.32

Sep 18, 2024 EST

Free Cash Flow

-$84.85M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$124.5M	$52.16M	$10.10M	$7.571M	$5.281M	$2.607M	$42.00M	$0.00	$24.03M	$31.62M	$28.93M	$5.410M
YoY Change	138.61%	416.57%	33.36%	43.36%	102.57%	-93.79%		-100.0%	-24.02%	9.32%	434.71%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$124.5M	$52.16M	$10.10M	$7.571M	$5.281M	$2.607M	$42.00M	$0.00	$24.03M	$31.62M	$28.93M	$5.410M
Cost Of Revenue	$17.80M	$4.117M	$1.000M	$145.0K	$600.0K	$466.0K	$8.400M
Gross Profit	$106.7M	$48.04M	$9.097M	$7.426M	$4.681M	$2.141M	$33.60M
Gross Profit Margin	85.7%	92.11%	90.1%	98.08%	88.64%	82.13%	80.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$134.4M	$76.60M	$68.80M	$33.15M	$24.27M	$23.72M	$23.23M	$18.73M	$13.53M	$7.290M	$3.700M	$4.030M
YoY Change	75.46%	11.33%	107.55%	36.59%	2.32%	2.11%	24.03%	38.43%	85.6%	97.03%	-8.19%
% of Gross Profit	126.01%	159.45%	756.33%	446.4%	518.48%	1107.89%	69.14%
Research & Development	$35.54M	$35.20M	$91.14M	$65.05M	$71.68M	$69.37M	$75.48M	$94.16M	$39.89M	$25.90M	$28.09M	$10.18M
YoY Change	0.95%	-61.38%	40.1%	-9.24%	3.32%	-8.09%	-19.84%	136.08%	54.0%	-7.81%	175.85%
% of Gross Profit	33.32%	73.27%	1001.87%	876.02%	1531.23%	3240.21%	224.64%
Depreciation & Amortization	$1.292M	$1.144M	$1.400M	$1.800M	$2.500M	$2.678M	$2.640M	$1.295M	$829.0K	$302.0K	$592.0K	$680.0K
YoY Change	12.94%	-18.29%	-22.22%	-28.0%	-6.65%	1.44%	103.86%	56.21%	174.5%	-48.99%	-12.94%
% of Gross Profit	1.21%	2.38%	15.39%	24.24%	53.41%	125.08%	7.86%
Operating Expenses	$169.9M	$35.20M	$91.14M	$65.05M	$71.68M	$69.37M	$98.72M	$112.9M	$53.42M	$33.19M	$31.79M	$14.22M
YoY Change	382.76%	-61.38%	40.1%	-9.24%	3.32%	-29.73%	-12.56%	111.35%	60.95%	4.38%	123.66%
Operating Profit	-$63.28M	-$63.76M	-$154.3M	-$90.78M	-$91.26M	-$90.95M	-$65.12M	-$112.9M	-$29.39M	-$1.564M	-$2.865M	-$8.805M
YoY Change	-0.76%	-58.69%	70.02%	-0.53%	0.35%	39.66%	-42.32%	284.14%	1779.09%	-45.41%	-67.46%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$4.950M	$3.400M	$4.502M	$5.099M	$5.726M	$3.534M			$0.00	-$1.590M	-$3.510M	-$950.0K
YoY Change	45.59%	-24.48%	-11.71%	-10.95%	62.03%				-100.0%	-54.7%	269.47%
% of Operating Profit
Other Income/Expense, Net	$6.630M	$1.633M	$687.0K	$1.568M	$2.352M	$3.187M	$1.960M	$508.0K	-$261.0K	$10.00K	-$52.00K	-$30.00K
YoY Change	306.0%	137.7%	-56.19%	-33.33%	-26.2%	62.6%	285.83%	-294.64%	-2710.0%	-119.23%	73.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$65.52M	-$67.20M	-$158.2M	-$94.31M	-$94.64M	-$91.29M	-$63.16M	-$112.4M	-$29.65M	-$3.147M	-$6.423M	-$9.785M
YoY Change	-2.5%	-57.51%	67.7%	-0.34%	3.66%	44.54%	-43.8%	279.05%	842.17%	-51.0%	-34.36%
Income Tax	$547.0K	$8.000K	$4.000K	$2.000K	$303.0K	$4.000K	$1.180M	$0.00	-$29.00K	$67.00K	$141.0K	$0.00
% Of Pretax Income
Net Earnings	-$66.07M	-$67.21M	-$158.2M	-$94.31M	-$94.94M	-$91.30M	-$64.34M	-$112.4M	-$29.62M	-$3.214M	-$6.564M	-$9.785M
YoY Change	-1.7%	-57.51%	67.7%	-0.66%	3.99%	41.9%	-42.75%	279.42%	821.62%	-51.04%	-32.92%
Net Earnings / Revenue	-53.08%	-128.85%	-1566.46%	-1245.71%	-1797.77%	-3502.03%	-153.19%		-123.29%	-10.16%	-22.69%	-180.87%
Basic Earnings Per Share	-$0.30	-$0.42	-$1.52	-$1.05	-$1.47
Diluted Earnings Per Share	-$0.30	-$0.42	-$1.52	-$1.05	-$1.47	-$1.624M	-$1.356M	-$2.801M	-$1.294M	-$172.7K	-$381.4K	-$569.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$184.3M	$123.9M	$116.7M	$186.5M	$247.5M	$168.1M	$134.0M	$200.8M	$107.0M	$107.3M	$34.40M	$32.90M
YoY Change	48.74%	6.19%	-37.43%	-24.65%	47.23%	25.45%	-33.27%	87.66%	-0.28%	211.92%	4.56%
Cash & Equivalents	$18.64M	$84.31M	$71.18M	$91.00M	$181.1M	$78.80M	$75.40M	$74.60M	$107.0M	$107.3M	$34.40M	$32.90M
Short-Term Investments	$162.8M	$27.77M	$44.26M	$95.50M	$66.40M	$89.30M	$58.60M	$126.2M
Other Short-Term Assets	$27.33M	$18.68M	$16.46M	$8.200M	$3.800M	$3.200M	$4.900M	$3.200M	$5.000M	$1.200M	$1.000M	$900.0K
YoY Change	46.33%	13.49%	100.71%	115.79%	18.75%	-34.69%	53.13%	-36.0%	316.67%	20.0%	11.11%
Inventory	$12.45M	$3.282M
Prepaid Expenses
Receivables	$22.03M	$7.733M	$502.0K	$0.00	$800.0K	$5.100M	$10.80M		$0.00	$2.600M	$6.400M	$3.100M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$246.1M	$153.6M	$133.6M	$194.7M	$252.1M	$176.4M	$149.7M	$204.0M	$112.0M	$111.1M	$41.80M	$36.90M
YoY Change	60.23%	14.93%	-31.36%	-22.77%	42.91%	17.84%	-26.62%	82.14%	0.81%	165.79%	13.28%
Property, Plant & Equipment	$6.598M	$10.52M	$15.11M	$4.200M	$7.400M	$5.600M	$8.000M	$9.000M	$4.700M	$2.100M	$500.0K	$800.0K
YoY Change	-37.27%	-30.41%	259.86%	-43.24%	32.14%	-30.0%	-11.11%	91.49%	123.81%	320.0%	-37.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00	$2.100M
YoY Change			-100.0%
Other Assets	$44.87M	$25.95M	$1.150M	$600.0K	$300.0K	$1.400M	$200.0K	$100.0K	$200.0K	$200.0K	$500.0K	$200.0K
YoY Change	72.94%	2156.09%	91.67%	100.0%	-78.57%	600.0%	100.0%	-50.0%	0.0%	-60.0%	150.0%
Total Long-Term Assets	$51.47M	$36.46M	$16.26M	$6.900M	$7.700M	$6.900M	$8.200M	$9.100M	$4.900M	$2.300M	$1.100M	$1.000M
YoY Change	41.15%	124.19%	135.71%	-10.39%	11.59%	-15.85%	-9.89%	85.71%	113.04%	109.09%	10.0%
Total Assets	$297.6M	$190.1M	$149.9M	$201.6M	$259.8M	$183.3M	$157.9M	$213.1M	$116.9M	$113.4M	$42.90M	$37.90M
YoY Change
Accounts Payable	$11.14M	$10.86M	$4.277M	$5.600M	$2.200M	$1.100M	$3.900M	$5.600M	$2.800M	$3.100M	$2.300M	$1.100M
YoY Change	2.57%	153.89%	-23.63%	154.55%	100.0%	-71.79%	-30.36%	100.0%	-9.68%	34.78%	109.09%
Accrued Expenses	$30.03M	$21.28M	$14.98M	$12.80M	$12.60M	$14.60M	$13.20M	$12.90M	$4.900M	$2.400M	$1.000M	$1.700M
YoY Change	41.12%	42.09%	17.01%	1.59%	-13.7%	10.61%	2.33%	163.27%	104.17%	140.0%	-41.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$26.71M	$32.26M	$4.200M	$1.200M
YoY Change	-100.0%	-17.21%	668.19%	250.0%
Total Short-Term Liabilities	$50.39M	$65.60M	$52.82M	$28.40M	$22.20M	$17.70M	$17.90M	$19.20M	$7.700M	$21.50M	$17.10M	$16.80M
YoY Change	-23.18%	24.2%	85.99%	27.93%	25.42%	-1.12%	-6.77%	149.35%	-64.19%	25.73%	1.79%
Long-Term Debt	$49.82M	$0.00	$0.00	$46.60M	$48.80M	$49.20M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%	-4.51%	-0.81%
Other Long-Term Liabilities	$30.55M	$26.13M	$14.48M	$400.0K	$2.100M	$600.0K	$700.0K	$800.0K	$300.0K	$31.20M	$33.10M	$22.30M
YoY Change	16.89%	80.55%	3518.75%	-80.95%	250.0%	-14.29%	-12.5%	166.67%	-99.04%	-5.74%	48.43%
Total Long-Term Liabilities	$80.37M	$26.13M	$14.48M	$47.00M	$50.90M	$49.80M	$700.0K	$800.0K	$300.0K	$31.20M	$33.10M	$22.30M
YoY Change	207.53%	80.55%	-69.2%	-7.66%	2.21%	7014.29%	-12.5%	166.67%	-99.04%	-5.74%	48.43%
Total Liabilities	$130.8M	$91.74M	$67.30M	$75.50M	$73.10M	$67.50M	$18.60M	$20.00M	$8.000M	$52.70M	$50.20M	$39.10M
YoY Change	42.54%	36.32%	-10.87%	3.28%	8.3%	262.9%	-7.0%	150.0%	-84.82%	4.98%	28.39%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	219.3M shares	158.7M shares	104.2M shares	89.58M shares	64.48M shares
Diluted Shares Outstanding	219.3M shares	158.7M shares	104.2M shares	89.58M shares	64.48M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $1.389 Billion

About Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Fremont, California and currently employs 267 full-time employees. The company went IPO on 2014-06-19. The firm focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The company has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Industry: Pharmaceutical Preparations Peers: Actinium Pharmaceuticals Inc Acumen Pharmaceuticals Inc Akouos, Inc. Clene Inc. LENZ Therapeutics Inc VBI Vaccines Inc Oyster Point Pharma, Inc. ARS Pharmaceuticals Inc Verastem Inc